Abstract
Zebrafish models continue to gain popularity as in vivo models for drug discovery. Described in this overview are advantages and challenges of zebrafish drug screening, as well as a novel in vivo screen for immunomodulatory compounds using transgenic, T cell reporting zebrafish larvae designed for discovery of compounds targeting T cell leukemia. This assay system allows rapid screening of large numbers of compounds while avoiding the pitfalls of assays based on cell cultures, which lack biologic context and are afflicted by genomic instability. The rationale for this approach is based on similarities of immature normal T cells and developmentally arrested, malignant lymphoblasts in mammalian species. The screening algorithm has been used to identify a nontoxic compound with activity in both acute leukemia models and models of multiple sclerosis, demonstrating the utility of this screening procedure. Curr. Protoc. Pharmacol.
Original language | English (US) |
---|---|
Article number | ph1424s60 |
Journal | Current Protocols in Pharmacology |
Issue number | SUPPL.60 |
DOIs | |
State | Published - 2013 |
Keywords
- Immunomodulatory agents
- Leukemia
- Liver cancer
- Melanoma
- Multiple sclerosis
- Pancreatic carcinoma
- Rhabdomyosarcoma
- Small molecule drug screening
- Testicular cancer
- Zebrafish
ASJC Scopus subject areas
- Pharmacology